Angiotensin II–HIF-1α Axis Regulates Ferroptosis and Radiosensitivity in Nasopharyngeal Carcinoma

Study Background and Research Question

Nasopharyngeal carcinoma (NPC) is a malignancy originating from the mucosal epithelium of the nasopharynx, with a high incidence in East and Southeast Asia. Despite radiotherapy being the mainstay of treatment due to the inherent radiosensitivity of NPC, a significant subset of patients experiences recurrence or residual disease, primarily driven by the emergence of radioresistance. The precise mechanisms underlying this resistance remain incompletely understood, impeding the development of effective radiosensitizing strategies. Recent interest has centered on the role of ferroptosis—a form of regulated cell death characterized by iron-dependent lipid peroxidation—in modulating tumor response to therapy. The reference study (Chen et al., 2025) addresses a critical gap by elucidating how the local renin-angiotensin system (RAS), particularly angiotensin II (Ang II), impacts ferroptosis and consequently, radiosensitivity in NPC.

Key Innovation from the Reference Study

The primary innovation lies in the identification of a local Ang II–driven feedback loop involving hypoxia-inducible factor-1 alpha (HIF-1α) and hypoxia-inducible lipid droplet-associated protein (HILPDA), leading to enhanced lipid droplet accumulation and suppression of ferroptosis in NPC cells. This axis, in turn, promotes tumor radioresistance. By unraveling how Ang II stabilizes HIF-1α both through MAPK pathway activation and direct binding with angiotensinogen (AGT), the study provides a mechanistic link between tumor microenvironmental cues, redox biology, and therapeutic response. It further identifies AGT, HIF-1α, HILPDA, and the antioxidant enzyme GPX4 as potential predictive biomarkers for radiosensitivity and prognosis in NPC (Chen et al., 2025).

Methods and Experimental Design Insights

The researchers established radioresistant NPC cell lines (HONE1-RR and SUNE1-RR) and used a multi-modal approach to dissect the signaling axis:

• Molecular profiling: Quantitative RT-PCR, western blotting, and ELISA to measure expression and activation of AGT, Ang II, HIF-1α, HILPDA, and GPX4.
• Ferroptosis assessment: Transmission electron microscopy to detect ultrastructural changes, ferrous ion quantification, and lipid peroxidation assays to monitor ferroptotic activity post-irradiation.
• Mechanistic dissection: Bioinformatics, co-immunoprecipitation, and dual-luciferase reporter assays to map the downstream interactions and transcriptional regulation within the pathway.
• Functional validation: Colony formation, Cell Counting Kit-8 (CCK8) proliferation assays, and in vivo studies using a nude mouse xenograft model to assess tumor radiosensitivity and growth.
• Tissue validation: Immunohistochemical analysis of clinical NPC samples for AGT, HIF-1α, HILPDA, and GPX4 expression patterns.

Protocol Parameters

• Cell line radioresistance induction: Chronic exposure of NPC cell lines to fractionated irradiation until radioresistant phenotype is established.
• Ferroptosis detection: Measurement of ferrous ion (Fe2+) levels and lipid peroxidation by colorimetric or fluorometric assays post-radiation.
• In vivo radiosensitization: Subcutaneous inoculation of NPC cells into nude mice, followed by administration of Ang II receptor blockers and/or ferroptosis inducers, with tumor volume monitoring after irradiation.
• Gene/protein expression quantification: Use of qRT-PCR and immunohistochemistry to assess AGT, HIF-1α, HILPDA, and GPX4 in tissue samples.

Core Findings and Why They Matter

The study demonstrates that local Ang II activation in NPC tissues suppresses ferroptosis, thereby conferring radioresistance. Mechanistically, Ang II enhances HIF-1α stability via two converging routes: MAPK pathway activation and direct AGT–HIF-1α interaction, which protects HIF-1α from degradation. HIF-1α transcriptionally upregulates HILPDA, promoting lipid droplet accumulation that impedes lipid peroxidation—a critical trigger for ferroptosis. GPX4, the central lipid hydroperoxidase, is also upregulated in this context, further supporting redox homeostasis and cell survival. Importantly, the combined use of Ang II receptor antagonists and ferroptosis inducers significantly increases NPC radiosensitivity in both cell culture and xenograft models (Chen et al., 2025).

This mechanistic insight positions the AGT–HIF-1α–HILPDA–GPX4 axis as a key determinant of NPC therapeutic response, offering potential targets for radiosensitization. The close correlation between the expression of these molecules and NPC patient prognosis also supports their utility as biomarkers.

Comparison with Existing Internal Articles

Several in-depth analyses, such as "Unlocking Translational Potential: RSL3 and the Next Frontier in Ferroptosis Research" and "RSL3 and the Ferroptosis Signaling Axis", have emphasized the role of RSL3, a potent glutathione peroxidase 4 inhibitor, as a precision tool for inducing ferroptosis and exploiting redox vulnerabilities in tumor biology. These articles correlate well with the reference study’s findings, especially regarding the centrality of GPX4 in regulating ferroptosis and the potential for synthetic lethality in RAS-driven tumors. Notably, the current study extends these discussions by mapping the upstream regulatory network (Ang II–HIF-1α–HILPDA) that controls GPX4 activity and ferroptosis in the specific context of NPC radioresistance.

Furthermore, "RSL3: Unveiling Ferroptosis Networks and Synthetic Lethality" (link) discusses the application of RSL3 for studying non-apoptotic cell death pathways, providing practical protocols that align with the radioresistant NPC models described in the reference paper.

Limitations and Transferability

While the findings robustly link the local Ang II–HIF-1α–HILPDA axis to ferroptosis suppression and radioresistance in NPC, there are some limitations:

• Tumor specificity: The identified mechanism is characterized in NPC; transferability to other tumor types or microenvironments requires further exploration.
• Therapeutic targeting: Although Ang II receptor blockers and ferroptosis inducers show synergistic effects in preclinical models, optimal dosing, delivery, and safety profiles need to be established in clinical trials.
• Biomarker validation: Larger cohorts are necessary to verify the prognostic and predictive value of AGT, HIF-1α, HILPDA, and GPX4 expression in NPC and potentially other cancers.

Why this cross-domain matters, maturity, and limitations

The convergence of cardiovascular hormone signaling (Ang II), hypoxia biology (HIF-1α), and ferroptotic cell death pathways provides a compelling rationale for cross-domain translational research. However, clinical adoption will require detailed safety and efficacy assessments, as well as validation in heterogeneous patient populations beyond NPC.

Research Support Resources

Researchers seeking to investigate ferroptosis modulation in cancer biology, or to design radiosensitization protocols that target the Ang II–HIF-1α–GPX4 axis, may benefit from using well-characterized ferroptosis inducers. (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor (SKU B6095) from APExBIO is a potent, selective tool for inducing ferroptosis and probing redox regulatory mechanisms in tumor models. RSL3 can be integrated into workflows studying oxidative stress, lipid peroxidation, and synthetic lethality in RAS-driven or radioresistant cancer systems, as highlighted by the reference study and supporting internal literature. For optimal performance, researchers should follow established protocols and consider freshly preparing solutions as recommended by the manufacturer.